Compare SOTK & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOTK | TELA |
|---|---|---|
| Founded | 1975 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.6M | 51.2M |
| IPO Year | 1987 | 2019 |
| Metric | SOTK | TELA |
|---|---|---|
| Price | $3.91 | $1.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $3.31 |
| AVG Volume (30 Days) | 17.4K | ★ 343.3K |
| Earning Date | 01-12-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 6.63 | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | $20,607,030.00 | ★ $77,055,000.00 |
| Revenue This Year | $2.67 | $18.39 |
| Revenue Next Year | $8.20 | $15.34 |
| P/E Ratio | $40.48 | ★ N/A |
| Revenue Growth | N/A | ★ 12.24 |
| 52 Week Low | $3.23 | $0.86 |
| 52 Week High | $6.05 | $3.12 |
| Indicator | SOTK | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 39.12 | 43.48 |
| Support Level | $3.40 | $1.09 |
| Resistance Level | $3.93 | $1.28 |
| Average True Range (ATR) | 0.20 | 0.11 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 33.63 | 60.00 |
Sono-Tek Corp design and manufacture of ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial and emerging research & development/other markets. The company design and manufacture custom-engineered ultrasonic coating systems incorporating its patented technology, in combination with strong applications engineering knowledge, to assist its customers in achieving their desired coating solutions.
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.